Long-Term Safety and Efficacy of Drug-Eluting Stents
| Autor: | Alberto Cremonesi, Enrico Aurier, Aleardo Maresta, Elisabetta Varani, Antonio Manari, Paolo Guastaroba, Gianfranco Percoco, Paolo Magnavacchi, Giancarlo Piovaccari, Alberto Benassi, Roberto Grilli, Francesco Saia, Antonio Marzocchi |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
Drug medicine.medical_specialty Ticlopidine Paclitaxel media_common.quotation_subject medicine.medical_treatment Myocardial Infarction Kaplan-Meier Estimate Coronary Angiography Revascularization Coronary Restenosis Risk Factors Physiology (medical) Diabetes Mellitus medicine Humans Prospective Studies Registries Renal Insufficiency Angioplasty Balloon Coronary Aged Proportional Hazards Models media_common Drug Implants Sirolimus Aspirin business.industry Coronary Thrombosis Incidence Coronary Stenosis Stent Middle Aged medicine.disease Combined Modality Therapy Coronary Vessels Clopidogrel Treatment Outcome Emergency medicine Female Stents Long term safety Medical emergency Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors Follow-Up Studies |
| Zdroj: | Circulation. 115:3181-3188 |
| ISSN: | 1524-4539 0009-7322 |
| Popis: | Background— The long-term safety and efficacy of drug-eluting stents (DES) have been questioned recently. Methods and Results— Between July 2002 and June 2005, 10 629 patients undergoing elective percutaneous coronary intervention with either DES (n=3064) or bare-metal stents (BMS, n=7565) were enrolled in a prospective registry comprising 13 hospitals. We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up. A propensity score analysis to adjust for different baseline clinical, angiographic, and procedural characteristics was performed. The 2-year unadjusted cumulative incidence of major adverse cardiac events was 17.8% in the DES group and 21.0% in the BMS group ( P =0.003 by log-rank test). Angiographic stent thrombosis was 1.0% in the DES group and 0.6% in the BMS group ( P =0.09). After adjustment, the 2-year cumulative incidence of death was 6.8% in the DES group and 7.4% in the BMS group ( P =0.35), whereas the rates were 5.3% in DES and 5.8% in BMS for acute myocardial infarction ( P =0.46), 9.1% in DES and 12.9% in BMS for target-vessel revascularization ( P P Conclusions— In this large real-world population, the beneficial effect of DES in reducing the need for new revascularization compared with BMS extends to 2 years without evidence of a worse safety profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|